Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Keep Limits On Off-Label Promotion, Consumers And Patients Say

Executive Summary

Prescribers can get information they need through continuing education programs and scientific conferences, non-industry stakeholders tell US FDA during second day of meeting on manufacturer communications for unapproved uses.


Related Content

Off-Label Wish List: Industry Groups Want US FDA's Guidances To Do More
Off-Label Promotion: 'Safe Harbor' Preferable To Expansive Free Speech Rulings
Off-Label Communication: Pfizer Highlights Burdens Of FDA Policy
Off-Label Communication Growth: Could FDA Afford To Police It?
Off-Label Communications: Industry, FDA Debate Role Of Peer Review





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts